MedTrace Logo

Exploration of Gemfibrozil as a Treatment for AUD

NCT03539432 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2021-10-29

Study results available
· View outcomes & findings →

Summary

This study will examine the efficacy of the medication gemfibrozil in reducing alcohol consumption in individuals with an alcohol use disorder who are seeking treatment for alcohol-related problems. Twenty individuals will be randomized to receive four weeks of either gemfibrozil or placebo and retrospective reports of alcohol use will be collected throughout the trial. In addition, brain imaging measures will be collected at baseline and after two weeks of treatment to determine the effects of gemfibrozil on brain functioning.

Conditions

Interventions

DRUG

Gemfibrozil 600 MG

Gemfibrozil capsules (600 mg) taken twice per day

DRUG

Placebo oral capsule

Microcrystalline cellulose powder packaged in capsules identical to the experimental medication

Sponsors & Collaborators

  • The Mind Research Network

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-16
Primary Completion
2018-12-30
Completion
2018-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03539432 on ClinicalTrials.gov